Oleg Tcheremissine, MD
Psychiatry · Charlotte, NCNPI 1710911755
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,900 of the $17,639 with a category attached, or 67.5%. Alkermes, Inc. accounts for 75.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $13,553 and has fallen 89.9% since, to $1,374 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $391.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$13K
- Neurocrine Biosciences, Inc.$3K
- Boehringer Ingelheim$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$280
- Acadia Pharmaceuticals Inc$172
- Otsuka America Pharmaceutical, Inc.$46
- plus $38 from 1 others
Across 131 payments — averaging $15,148 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.4M
- Janssen Scientific Affairs, LLC$267K
- Eli Lilly$255K
- Boehringer Ingelheim International GmbH$28K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
- Corcept Therapeutics$13K
What the payments were for
- Speaking & faculty fees$11,90067%
- Travel & lodging$3,51120%
- Food & beverage$2,19012%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 13 | $13,296 |
| Neurocrine Biosciences, Inc. | 17 | $2,532 |
| Boehringer Ingelheim | 9 | $1,273 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $280 |
| Acadia Pharmaceuticals Inc | 1 | $172 |
| Otsuka America Pharmaceutical, Inc. | 1 | $46 |
| Genentech, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,639 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 47 | $367,144 |
| RexultiBrexpiprazole | 24 | $33,237 |
| Invega SustennaPaliperidone Palmitate | 13 | $30,223 |
| Lurasidone Hcl | 70 | $21,790 |
| VraylarCariprazine Hcl | 13 | $21,578 |
| LatudaLurasidone Hcl | 14 | $18,824 |
| Clozapine | 170 | $13,568 |
| Paliperidone ErPaliperidone | 82 | $10,005 |
| RisperdalRisperidone | 13 | $5,122 |
| Aripiprazole | 85 | $4,687 |
| Clozapine OdtClozapine | 19 | $4,452 |
| Olanzapine | 118 | $4,069 |
| Risperidone | 218 | $3,839 |
| Divalproex Sodium ErDivalproex Sodium | 81 | $3,309 |
| Quetiapine Fumarate | 195 | $2,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,532 | $367,14447 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $46 | $33,23724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Charlotte
- Devendra ShahCharlotte$24K
- Kenneth RichmondCharlotte$15K
- Preetinder BrarCharlotte$13K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.